Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy RSS feedThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Serum potassium response to single ‐dose sodium zirconium cyclosilicate for the treatment of asymptomatic hyperkalemia in hospitalized patients
AbstractAsymptomatic hyperkalemia can be treated with oral potassium binders. Sodium polystyrene sulfonate (SPS) remains widely utilized despite association with serious adverse events including intestinal necrosis. Sodium zirconium cyclosilicate (SZC) is an alternative that has demonstrated a better safety profile and faster onset. SZC's approved initial dosing is 10 g orally three times daily (TID) for 48 hours, which is how available studies evaluate SZC. The purpose of this study was to assess the efficacy of single-dose SZC compared to TID dosing and to single-dose SPS for the management of asymptomatic hyperkalemia i...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - July 21, 2023 Category: Drugs & Pharmacology Authors: Haley Lewis, Benton Stamper, Alyssa Claudio Yungkurth Tags: RESEARCH ARTICLE Source Type: research

Theophylline for the management of respiratory disorders in adults in the 21st century: A scoping review from the American College of Clinical Pharmacy Pulmonary Practice and Research Network
AbstractTheophylline is an oral methylxanthine bronchodilator recommended as alternate therapy for the treatment of asthma and chronic obstructive pulmonary disease (COPD). However, it is not generally recommended for the treatment of other respiratory disorders such as obstructive sleep apnea (OSA) or hypoxia. Most clinical practice guidelines rely on evidence published prior to the year 2000 to make these recommendations. This scoping review aimed to gather and characterize evidence describing theophylline for the management of respiratory disorders in adults between January 1, 2000 and December 31, 2020. Databases searc...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - July 20, 2023 Category: Drugs & Pharmacology Authors: Paul M. Boylan, Maha Abdalla, Brittany Bissell, Mark A. Malesker, Melissa Santiba ñez, Zachary Smith Tags: REVIEW Source Type: research

Antithrombotic Therapy with Transcatheter Aortic Valve Replacement
AbstractAortic valve replacement is a necessary management strategy for patients with severe aortic stenosis. The use of transaortic valve replacement (TAVR) has increased significantly over the last decade and now exceeds traditional surgical aortic valve replacement. Since the valve systems used in TAVR consist of bioprosthetic valve tissue encased in a metal stent frame, antithrombotic therapy recommendations cannot be extrapolated from prior data with differently constructed surgical bioprosthetic or mechanical valves. Data on the use of antithrombotic therapy with TAVR are a rapidly developing area of medicine. Choice...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - July 19, 2023 Category: Drugs & Pharmacology Authors: Paul P. Dobesh, Andrew M. Goldsweig Tags: REVIEW Source Type: research

Role of Lipoprotein(a) in Atherosclerotic Cardiovascular Disease: A Review of Current and Emerging Therapies
AbstractLipoprotein(a), or Lp(a), is structurally like low-density lipoprotein (LDL) but differs in that it contains glycoprotein apolipoprotein(a) [apo(a)]. Due to its prothrombotic and proinflammatory properties, Lp(a) is an independent risk factor for atherosclerotic cardiovascular disease (ASCVD) and aortic valve stenosis. Lp(a) levels are genetically determined, and it is estimated that 20-25% of the global population has an Lp(a) level ≥50 mg/dL (or ≥125 nmol/L). Diet and lifestyle interventions have little to no effect on Lp(a) levels. Lipoprotein apheresis is the only approved treatment for elevated Lp(a) but i...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - July 19, 2023 Category: Drugs & Pharmacology Authors: Ibrahim S. Alhomoud, Azita Talasaz, Anurag Mehta, Michael Kelly, Evan M. Sisson, John D. Bucheit, Roy Brown, Dave L. Dixon Tags: REVIEW Source Type: research

Comparative effectiveness of sodium ‐glucose cotransporter‐2 inhibitors among patients with heart failure with preserved ejection fraction
ConclusionsCompared with canagliflozin or dapagliflozin use, empagliflozin use was associated with decreased risk of HF-related and all-cause hospitalizations. Compared with canagliflozin, dapagliflozin was associated with a reduced risk of HF-related and all-cause hospitalizations. (Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy)
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - July 18, 2023 Category: Drugs & Pharmacology Authors: Munaza Riaz, Steven M. Smith, Eric A. Dietrich, David E. Winchester, Jingchuan Guo, Haesuk Park Tags: RESEARCH ARTICLE Source Type: research

Utility of Triazole Antifungal Therapeutic Drug Monitoring: Insights from the Society of Infectious Diseases Pharmacists
AbstractTriazole antifungals (i.e., fluconazole, itraconazole, voriconazole, posaconazole, isavuconazole) are commonly used in clinical practice to prevent or treat invasive fungal infections. Most triazole antifungals require therapeutic drug monitoring (TDM) due to highly variable pharmacokinetics, known drug interactions, and established relationships between exposure and response. On behalf of the Society of Infectious Diseases Pharmacists (SIDP), this insight describes the pharmacokinetic principles and pharmacodynamic targets of commonly used triazole antifungals and provides the rationale for utility of TDM within e...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - July 17, 2023 Category: Drugs & Pharmacology Authors: Erin K. McCreary, Matthew R. Davis, Navaneeth Narayanan, David R. Andes, Dario Cattaneo, Robbie Christian, Russell E. Lewis, Kevin M. Watt, Nathan P. Wiederhold, Melissa D. Johnson Tags: REVIEW Source Type: research

Vancomycin Dosing In High ‐Intensity Continuous Renal Replacement Therapy: A Retrospective Cohort Study
ConclusionThis is the first study to evaluate the influence of variable CRRT intensities on vancomycin AUC/MIC. Our findings suggest that vancomycin doses ≥ 15 mg/kg/day are needed to achieve early therapeutic targets in patients on high-intensity CRRT. (Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy)
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - July 17, 2023 Category: Drugs & Pharmacology Authors: Nina Srour, Chelsea Lopez, Luma Succar, Peter Nguyen Tags: RESEARCH ARTICLE Source Type: research

Fracture risk and opioid use in patients aged 17 ‐64 years: An analysis of administrative claims data
ConclusionsWe observed an increased fracture risk in all three higher categories of opioid exposure relative to the lowest category (<22  MME). The risk of a fracture should be considered in opioid treatment decisions. (Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy)
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - July 17, 2023 Category: Drugs & Pharmacology Authors: Jonathan Davis, Carri Casteel, Grant Brown, Ryan Carnahan Tags: RESEARCH ARTICLE Source Type: research